medigraphic.com
ISSN 0138-7103 (Impreso)

2016, Número S1

<< Anterior Siguiente >>

Revista del Hospital Psiquiátrico de La Habana 2016; 13 (S1)


Psicosis y cannabis, dos caras en una moneda

Martínez HM

Idioma: Español
Referencias bibliográficas: 35
Paginas:
Archivo PDF: 80.40 Kb.


RESUMEN

En las últimas tres décadas se ha estado produciendo un consumo de cannabis altamente prevalente entre los jóvenes, lo que ha motivado disímiles controversias sobre los riesgos psicosociales de dicho consumo. De estos hay que destacar la posibilidad de que el cannabis sea un factor de riesgo de una enfermedad tan grave e incapacitante como la esquizofrenia. Entre las manifestaciones clínicas más comunes está la presencia de síntomas psicóticos, por lo que se infiere que este puede ser un factor de riesgo de la esquizofrenia en personas con una vulnerabilidad genética o psicosocial asociada. De ahí que sea necesaria la aplicación de medidas preventivas en los grupos de alto riesgo, que son fundamentalmente los consumidores de grandes cantidades de cannabis y aquellos que inician el consumo en la adolescencia temprana.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. 1.- Arias F, Sánchez S, Padín JJ. Relevancia del consumo de drogas en las manifestaciones clínicas de la esquizofrenia. Actas Españolas de Psiquiatría 2002; 30: 65-73.

  2. 2.- D’Souza DC, Perry E, MacDougall L, Ammerman Y, Cooper T, Wu YT, et al. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology 2004; 29: 1558-72.

  3. 3.- Caton CL, Drake RE, Hasin DS, Dominguez B, Shrout PE, Samet S, et al. Differences between early-phase primary psychotic disorders with concurrent substance use and substance-induced psychoses. Archives of General Psychiatry 2005; 62: 137-45.

  4. 4.- Potvin S, Sepehry AA, Stip E. A meta-analysis of negative symptoms in dual diagnosis schizophrenia. Psychological Medicine 2006; 36:431-40.

  5. 5.-Henquet C, Murray R, Linszen D, van Os J. The environment and schizophrenia: the role of cannabis use. Schizophrenia Bulletin 2005;31: 608-12.

  6. 6.- Bersani G, Orlandi V, Gherardelli S, Pancheri P. Cannabis and neurological soft signs in schizophrenia: absence of relationship and influence on psychopathology. Psychopathology 2002; 35: 289-95.

  7. 7.- Leweke FM, Gerth CW, Klosterkotter J. Cannabis-associated psychosis: current status of research. CNS Drugs 2004; 18:895-910.

  8. 8.- Caspi A, Moffitt TE, Cannon M, McClay J, Murray R, Harrington H, et al. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-Omethyltransferase gene: longitudinal evidence of a gene X environment. Biol Psychiatry. 2005 May 15;57(10):1117-27.

  9. 9.- Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. British Medical Journal 2002;325: 1212-3.

  10. 10.- Batel P. Addiction and schizophrenia. European Psychiatry 2000; 15: 115-22.

  11. 11.- Irala J, Ruiz-Canela M, Martínez-González MA. Causal relationship between cannabis use and psychotic symptoms or depression. Should we wait and see? A public health perspective. Medical Science Monitor: International Medical Journal of Experimental and Clinical Research, 2005; 11: 355-8.

  12. 12.- Talamo A, Centorrino F, Tondo L, Dimitri A, Hennen J, Baldessarini RJ. Comorbid substanceuse in schizophrenia: Relation to positive and negative symptoms. Schizophrenia Research 2006; 86: 251-5.

  13. 13.- Barnes TR, Mutsatsa SH, Hutton SB, Watt HC, Joyce EM. Comorbid substance use and age at onset of schizophrenia. British Journal of Psychiatry, 2006; 188: 237-42.

  14. 14.- Semple DM, McIntosh AM, Lawrie SM. Cannabis as a risk factor for psychosis: systematic review. Journal of Psychopharmacology, 2005; 19: 187-94.

  15. 15.- Favrat B, Menetrey A, Augsburger M, Rothuizen LE, Appenzeller, M, Buclin T, et al. Two cases of “cannabis acute psychosis” following the administration of oral cannabis. BMC Psychiatry 2005: 5, 17.

  16. 16.- Shakir SA, Layton D. Causal association in pharmacovigilance and pharmacoepidemiology: thoughts on the application of the Austin Bradford-Hill criteria. Drug Safety, 2002; 25: 467-71.

  17. 17.- Buhler B, Hambrecht M, Loffler W, van der Heiden W, Hafner H. Precipitation and determination of the onset and course of schizophrenia by substance abuse-a retrospective and prospective study of 232 population-based first illness episodes. Schizophrenia 2002: 15-19

  18. 18.- Arendt M, Rosenberg R, Foldager L, Perto G, Munk- Jorgensen P. Cannabis-induced psychosis and subsequent schizophrenia-spectrum disorders: follow-up study of 535 incident cases. British Journal of Psychiatry 2005; 187:510-5.

  19. 19.- Schiffman J, Nakamura B, Earleywine M, LaBrie J. Symptoms of schizotypy precede cannabis use. Psychiatry Research, 2005; 134:37-42.

  20. 20.- Green AI, Tohen MF, Hamer RM, Strakowski SM, Lieberman JA, Glick I, et al. First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol. Schizophrenia Research 2004; 66: 125-35.

  21. 21.- Núñez LA, Gurpegui M. Cannabis-induced psychosis: a cross-sectional comparison with acute schizophrenia. Acta Psychiatrica Scandinavica 2002; 105: 173-8.

  22. 22.- Arendt M, Munk-Jorgensen P. Heavy cannabis users seeking treatment- prevalence of psychiatric disorders. Social Psychiatry and Psychiatric Epidemiology 2004; 39: 97- 105.

  23. 23.- Dean B, Sundram S, Bradbury R, Scarr E, Copolov D. Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience 2001; 103: 9-15.

  24. 24.- Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. British Medical Journal 2002; 325: 1212-3.

  25. 25.- Skosnik PD, Spatz-Glenn L, Park S. Cannabis use is associated with schizotypy and attentional disinhibition. Schizophrenia Research 2001; 48:83-92.

  26. 26.-Kumra S, Thaden E, DeThomas C, Kranzler H. Correlates of substance abuse in adolescents with treatment-refractory schizophrenia and schizoaffective disorder. Schizophrenia Research, 73: 369-71.

  27. 27.- Jorgensen P. Cannabis-induced psychosis and subsequent schizophrenia-spectrum disorders: follow-up study of 535 incident cases. British Journal of Psychiatry 2005; 187: 510-5.

  28. 28.- Wade D. Cannabis use and schizophrenia. American Journal of Psychiatry 2005 :162, 401.

  29. 29.- Green B, Young R, Kavanagh D. Cannabis use and misuse prevalence among people with psychosis. British Journal of Psychiatry 2005; 187: 306-13.

  30. 30.- Caspi A, Moffitt TE, Cannon M, McClay J, Murray R, Harrington H, et al. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-Omethyltransferase gene: longitudinal evidence of a gene X environment interaction. Biological Psychiatry 2005; 57: 1117-27.

  31. 31.- Henquet C, Krabbendam L, Spauwen J, Kaplan C, Lieb R, Wittchen HU, et al. Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. British Medical Journal 2005; 330: 11.

  32. 32.- Hall W. Is cannabis use psychotogenic? Lancet 2006; 367: 193-5.

  33. 33.- Giuffrida A, Leweke FM, Gerth CW, Schreiber D, Koethe D, Faulhaber J, et al. Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology 2004; 29: 2108-14.

  34. 34.-De Marchi N, De Petrocellis L, Orlando P, Daniele F, Fezza F, Di Marzo V. Endocannabinoid signalling in the blood of patients with schizophrenia. Lipids Health Diseases 2003:2,5.

  35. 35.-Fergusson DM, Horwood LJ, Swain-Campbell NR. Cannabis dependence and psychotic symptoms in young people. Psychological Medicine 2003; 33: 15-




2020     |     www.medigraphic.com